A synergy between IR and TGFβ blockade, using therapeutic approaches other than gene therapy, has been previously reported.7–10 In line with this, in our study TGFβ-blocking HSC gene therapy combined with IR significantly reduced tumor burden as compared with monotherapies. This evidence concerns the gene TGFB1 and neoplasm.